文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

一种用于通用流感 A 疫苗候选物 M2e 的单次注射疫苗方法。

A single-shot vaccine approach for the universal influenza A vaccine candidate M2e.

机构信息

Infectious Diseases Translational Research Programme, Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.

Life Sciences Institute, Immunology Programme, National University of Singapore, Singapore.

出版信息

Proc Natl Acad Sci U S A. 2022 Mar 29;119(13):e2025607119. doi: 10.1073/pnas.2025607119. Epub 2022 Mar 23.

DOI:10.1073/pnas.2025607119
PMID:35320040
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9060463/
Abstract

SignificanceAlthough the need for a universal influenza vaccine has long been recognized, only a handful of candidates have been identified so far, with even fewer advancing in the clinical pipeline. The 24-amino acid ectodomain of M2 protein (M2e) has been developed over the past two decades. However, M2e-based vaccine candidates have shortcomings, including the need for several administrations and the lack of sustained antibody titers over time. We report here a vaccine targeting strategy that has the potential to confer sustained and strong protection upon a single shot of a small amount of M2e antigen. The current COVID-19 pandemic has highlighted the importance of developing versatile, powerful platforms for the rapid deployment of vaccines against any incoming threat.

摘要

意义 尽管人们早就认识到需要一种通用的流感疫苗，但迄今为止，只有少数候选疫苗被确定，而在临床研发管道中推进的候选疫苗则更少。过去二十年来，M2 蛋白（M2e）的 24 个氨基酸的外结构域已经得到了发展。然而，基于 M2e 的疫苗候选物存在一些缺点，包括需要多次接种以及随着时间的推移抗体滴度不能持续。我们在此报告了一种疫苗靶向策略，该策略有可能在单次注射少量 M2e 抗原时提供持续且强大的保护。当前的 COVID-19 大流行凸显了开发多功能、强大平台的重要性，以便能够快速部署针对任何传入威胁的疫苗。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fb58/9060463/2bc9c801a310/pnas.2025607119fig07.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fb58/9060463/4af298e10b59/pnas.2025607119fig01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fb58/9060463/46eef448de2a/pnas.2025607119fig02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fb58/9060463/c18181d6e353/pnas.2025607119fig03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fb58/9060463/90c79590289b/pnas.2025607119fig04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fb58/9060463/4edc11db752f/pnas.2025607119fig05.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fb58/9060463/27aae90d1210/pnas.2025607119fig06.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fb58/9060463/2bc9c801a310/pnas.2025607119fig07.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fb58/9060463/4af298e10b59/pnas.2025607119fig01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fb58/9060463/46eef448de2a/pnas.2025607119fig02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fb58/9060463/c18181d6e353/pnas.2025607119fig03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fb58/9060463/90c79590289b/pnas.2025607119fig04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fb58/9060463/4edc11db752f/pnas.2025607119fig05.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fb58/9060463/27aae90d1210/pnas.2025607119fig06.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fb58/9060463/2bc9c801a310/pnas.2025607119fig07.jpg

相似文献

[1]
A single-shot vaccine approach for the universal influenza A vaccine candidate M2e.

Proc Natl Acad Sci U S A. 2022-3-29

[2]
Sublingual immunization with M2-based vaccine induces broad protective immunity against influenza.

PLoS One. 2011-11-30

[3]
Intranasal adenovirus-vectored vaccine for induction of long-lasting humoral immunity-mediated broad protection against influenza in mice.

J Virol. 2014-9-1

[4]
The Role of Matrix Protein 2 Ectodomain in the Development of Universal Influenza Vaccines.

J Infect Dis. 2019-4-8

[5]
Bacteriophage T4 Vaccine Platform for Next-Generation Influenza Vaccine Development.

Front Immunol. 2021

[6]
Protection against multiple influenza A virus strains induced by candidate recombinant vaccine based on heterologous M2e peptides linked to flagellin.

PLoS One. 2015-3-23

[7]
Protection against the H1N1 influenza virus using self-assembled nanoparticles formed by lumazine synthase and bearing the M2e peptide.

Virology. 2024-9

[8]
An H5N1-based matrix protein 2 ectodomain tetrameric peptide vaccine provides cross-protection against lethal infection with H7N9 influenza virus.

Emerg Microbes Infect. 2015-4

[9]
Improving Cross-Protection against Influenza Virus Using Recombinant Vaccinia Vaccine Expressing NP and M2 Ectodomain Tandem Repeats.

Virol Sin. 2019-6-25

[10]
Characterization of the murine Th2 response to immunization with liposomal M2e influenza vaccine.

Vaccine. 2011-5-3

引用本文的文献

[1]
Epitope-focused vaccine immunogens design using tailored horseshoe-shaped scaffold.

J Nanobiotechnology. 2025-2-18

[2]
Proteolysis-targeting influenza vaccine strains induce broad-spectrum immunity and in vivo protection.

Nat Microbiol. 2025-2

[3]
Multifaceted virus-like particles: Navigating towards broadly effective influenza A virus vaccines.

Curr Res Microb Sci. 2024-11-15

[4]
A Single-Component Multilayered Self-Assembling Protein Nanoparticle Vaccine Based on Extracellular Domains of Matrix Protein 2 against Both Influenza A and B.

Vaccines (Basel). 2024-8-28

[5]
Engineered probiotic Escherichia coli elicits immediate and long-term protection against influenza A virus in mice.

Nat Commun. 2024-8-9

[6]
Bacteriophage T4 as a Protein-Based, Adjuvant- and Needle-Free, Mucosal Pandemic Vaccine Design Platform.

Annu Rev Virol. 2024-9

[7]
Single-shot dendritic cell targeting SARS-CoV-2 vaccine candidate induces broad, durable and protective systemic and mucosal immunity in mice.

Mol Ther. 2024-7-3

[8]
Recent Advances, Approaches and Challenges in the Development of Universal Influenza Vaccines.

Influenza Other Respir Viruses. 2024-3

[9]
A novel "prime and pull" strategy mediated by the combination of two dendritic cell-targeting designs induced protective lung tissue-resident memory T cells against H1N1 influenza virus challenge.

J Nanobiotechnology. 2023-12-13

[10]
An mRNA-based broad-spectrum vaccine candidate confers cross-protection against heterosubtypic influenza A viruses.

Emerg Microbes Infect. 2023-12

本文引用的文献

[1]
A Decade in Review: A Systematic Review of Universal Influenza Vaccines in Clinical Trials during the 2010 Decade.

Viruses. 2020-10-20

[2]
Progress in the Development of Universal Influenza Vaccines.

Viruses. 2020-9-17

[3]
Display of Native Antigen on cDC1 That Have Spatial Access to Both T and B Cells Underlies Efficient Humoral Vaccination.

J Immunol. 2020-10-1

[4]
Double-Layered M2e-NA Protein Nanoparticle Immunization Induces Broad Cross-Protection against Different Influenza Viruses in Mice.

Adv Healthc Mater. 2020-1

[5]
Advancing immunomodulation by in vivo antigen delivery to DEC-205 and other cell surface molecules using recombinant chimeric antibodies.

Int Immunopharmacol. 2019-6-19

[6]
Targeting M2e to DEC-205 induces an enhanced serum antibody-dependent heterosubtypic protection against influenza A virus infection.

Vaccine. 2019-4-5

[7]
CD8XCR1 Dendritic Cells Express High Levels of Toll-Like Receptor 5 and a Unique Complement of Endocytic Receptors.

Front Immunol. 2019-1-16

[8]
Influenza vaccine: Where are we and where do we go?

Rev Med Virol. 2018-11-8

[9]
Cross-Protective Immune Responses Induced by Sequential Influenza Virus Infection and by Sequential Vaccination With Inactivated Influenza Vaccines.

Front Immunol. 2018-10-9

[10]
Universal Influenza Vaccines: Progress in Achieving Broad Cross-Protection In Vivo.

Am J Epidemiol. 2018-12-1

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索